What does ibogaine do and what is it used for?

Ibogaine is the primary active compound of the West African iboga plant. The substance causes intense hallucinations and has been used for centuries by the Bwiti and Mbiri tribes in religious ceremonies. In modern science, interest has been driven mainly by its potential effect on addiction.

The most researched application is in opioid addiction. Open-label studies and one randomised controlled trial show that a single dose of ibogaine can reduce opioid craving by 50% or more, and that this effect persists for up to 24 weeks. In a case series of 33 patients, withdrawal symptoms disappeared within 24 hours in 25 of them. That sounds promising, but only one double-blind placebo-controlled trial is available to date, which means the evidence base is still narrow.

Animal research also shows reduced use of cocaine, amphetamines and nicotine following ibogaine, but whether this effect occurs in humans has not been demonstrated. One small observational study without a control group in 30 military veterans with traumatic brain injury reported that the majority experienced less PTSD, depression and anxiety one month after treatment. These are preliminary findings that cannot yet be generalised to broader populations.

The safety risks are serious and well documented. Ibogaine prolongs the QT interval in the heart, which can lead to fatal cardiac arrhythmias. Deaths from cardiac arrest have been reported even in clinical studies. At higher doses the substance is also toxic to nerve cells. Temporary side effects such as balance disturbances, tremors and gastrointestinal complaints occur regularly; mania or psychosis are rarer but more serious. Patients using long-acting opioids must have fully tapered off before ibogaine can even be considered, due to dangerous interactions. Preliminary research suggests that magnesium may partly reduce the cardiac risks, but this has not yet been studied sufficiently.

Because ibogaine acts through multiple brain systems simultaneously, its exact mechanism of action has not yet been fully elucidated. Researchers are working on less risky chemical variants with comparable effects, but clinical trials with these compounds are still largely yet to begin. In many countries, including the Netherlands, ibogaine is a controlled substance. Use outside of medical supervision carries a real and serious risk to life.